Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Iradimed (IRMD) Equity Average (2016 - 2025)

Historic Equity Average for Iradimed (IRMD) over the last 12 years, with Q3 2025 value amounting to $96.3 million.

  • Iradimed's Equity Average rose 1811.68% to $96.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $96.3 million, marking a year-over-year increase of 1811.68%. This contributed to the annual value of $79.1 million for FY2024, which is 906.02% up from last year.
  • Per Iradimed's latest filing, its Equity Average stood at $96.3 million for Q3 2025, which was up 1811.68% from $92.2 million recorded in Q2 2025.
  • In the past 5 years, Iradimed's Equity Average registered a high of $96.3 million during Q3 2025, and its lowest value of $62.2 million during Q1 2021.
  • In the last 5 years, Iradimed's Equity Average had a median value of $71.7 million in 2022 and averaged $74.2 million.
  • Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 36.48% in 2022, then skyrocketed by 1988.02% in 2025.
  • Quarter analysis of 5 years shows Iradimed's Equity Average stood at $70.0 million in 2021, then grew by 2.41% to $71.7 million in 2022, then increased by 1.77% to $73.0 million in 2023, then grew by 16.62% to $85.1 million in 2024, then increased by 13.16% to $96.3 million in 2025.
  • Its last three reported values are $96.3 million in Q3 2025, $92.2 million for Q2 2025, and $88.4 million during Q1 2025.